FM
funds managed by abrdn Inc.
funds managed by abrdn Inc. is a Series A to Series C stage investment firm. It has made 8 investments. 75% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (50% of deals). Average disclosed round size is $127.8M (across 6 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Epicrispr Biotechnologies | Series C | $90M | Aug 2026 |
 Aviceda | Series C | — | Jan 2026 |
 Crystalys Therapeutics Inc | Series A | $205M | Sep 2025 |
| AAviceda Therapeutics | Series C | — | Jan 2025 |
 Nuvig Therapeutics | Series B | $161M | Dec 2024 |
| EEngrail | Series B | $157M | Mar 2024 |
 Qlaris Bio | Series B | $24M | — |
 Crystalys | Series B | $130M | — |
Top Co-Investors
Longwood Fund3 shared
Alexandria Venture Investments3 shared
Digitalis Ventures3 shared
Pontifax2 shared
SR One2 shared
Lightstone Ventures2 shared
Wedbush Healthcare Partners2 shared
Novo Holdings A/S2 shared
Catalys Pacific2 shared
Pivotal Life Sciences2 shared
Norwest Venture Partners2 shared
Sanofi Ventures2 shared
Cormorant Asset Management2 shared
Longitude Capital2 shared
Catalio Capital Management2 shared
Jeito Capital2 shared
Omega Funds2 shared
Logos Capital2 shared
Last updated: 7 October 2026